BURLINGAME, CA – March 18, 2020 – The Edison Awards winners were announced on March 18, 2020. The Cala Trio™ by Cala Health took the gold award for the Medical Device/Dental category.
Cala Trio is the only non-invasive individualized prescription therapy for hand tremor in adults with ET. The most prevalent tremor disorder and one of the most common neurological disorders, ET affects an estimated seven million people in the United States.
Cala Trio is a wrist-worn neuromodulation device. It is calibrated to each patient’s hand tremor and used on-demand. When activated, Cala Trio gently stimulates the nerves at the wrist, which interrupts the tremulous circuit in the brain and provides temporary and meaningful tremor reduction in the treated hand. For patients with ET, this means they can now complete daily tasks such as eating, writing, or getting dressed that were otherwise extremely difficult.
The safety and efficacy of Cala Trio was demonstrated in the largest therapeutic trial ever conducted for ET. Cala Trio is FDA cleared and available by prescription in the United States.
Among the nomination entries comprising the best products, services, and businesses in innovation for the year 2020, Cala Trio was chosen as a winner by a panel of over 3,000 leading business executives from around the world. “After a thorough review, the Edison Awards Judges recognize Cala Trio as a game-changing innovation standing out among the best new products and services launched in their category,” said Frank Bonafilia, Executive Director of the Edison Awards.
About Edison Awards
The Edison Awards is the world’s most revered Innovation Award dedicated to recognizing and honoring the best in innovation and innovators since 1987. For more information about the Edison Awards complete program and a list of past winners, visit EdisonAwards.com.
Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation, and its vertically integrated commercial model is reshaping the delivery of prescription therapies. Cala Health’s lead product, Cala Trio™, is the only non-invasive prescription therapy for essential tremor. New therapies are under development in neurology, cardiology, and psychiatry. Cala Health is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. For more information, visit CalaHealth.com.